EGFR and lung adenocarcinoma: Furthermore, research has also focused on identifying the epidermal growth factor receptor (EGFR) gene mutation status in lung adenocarcinoma, which is crucial for determining the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and thus beneficial for personalized patient care (17).